Investor Presentation for the Quarter and year ended 31st March 2026
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amrutanjan Health Care reported strong FY26 results with net sales of Rs. 502.55 Cr, up 11.23% YoY, and profit before exceptional items growing 25.47% to Rs. 86.74 Cr. Q4 FY26 saw net sales of Rs. 149.77 Cr (up 10.60%) with profit before exceptional items jumping 37.20% to Rs. 28.62 Cr. Pain Management (Rs. 342.1 Cr gross sales) and Women's Hygiene (Rs. 151.6 Cr) drove growth with double-digit increases. The company expanded distribution by adding 44,000 new chemist outlets (targeting 100,000 by September 2027) and launched new products including razors, antiseptic plasters, ortho pain oil, and nasal spray. Management noted one-time exceptional charges of Rs. 76 million for lease rent litigation and Rs. 12.5 million for new labour codes. They expect COGS inflation from Middle East geopolitical factors but plan to mitigate through price increases.
The company delivered robust operating profit growth driven by brand strength and distribution expansion, though exceptional items will impact Q4 bottom line. The new sanitary pad plant commencing in May should improve Comfy brand profitability, while COGS inflation remains a watch item for FY27.